Kathryn Starzyk
About Kathryn Starzyk
Kathryn Starzyk VP Real World Evidence
Kathryn Starzyk serves as the Vice President of Real World Evidence. With a pivotal role in this position, she focuses on leveraging real-world data to generate valuable insights that support healthcare decisions and strategies. Her responsibilities include overseeing the collection, analysis, and application of real-world evidence to enhance product safety, efficacy, and overall healthcare outcomes.
Kathryn Starzyk Senior Director Epidemiology Outcome Research
Prior to her current role, Kathryn Starzyk was the Senior Director of Epidemiology and Outcomes Research at Outcome, a company now integrated into the late phase division of IQVIA. In this capacity, she led various epidemiological studies and outcomes research projects, contributing significantly to understanding and managing health outcomes in diverse patient populations.
Kathryn Starzyk Education Background
Kathryn Starzyk holds an academic background from prestigious institutions. She graduated from Dartmouth College and later obtained an advanced degree from the Harvard T.H. Chan School of Public Health. These educational experiences have equipped her with a robust foundation in public health, epidemiology, and health outcomes research.
Kathryn Starzyk Research Experience NIH Columbia Harvard
Kathryn Starzyk has held significant research positions at renowned institutions including the National Institutes of Health (NIH), Columbia University, and Harvard University. These roles have provided her with extensive research experience, particularly in the areas of epidemiology, rare diseases, biologics, and gene therapy applications.
Kathryn Starzyk Expertise in Safety and Risk Management
Kathryn Starzyk has specialized expertise in safety and risk management, particularly for products ranging from clinical development through post-marketing. She is well-versed in navigating regulatory landscapes and ensuring the safety and efficacy of therapeutics, with a concentrated focus on rare diseases, biologics, and gene therapies.